rss
DTB 48:93-96 doi:10.1136/dtb.2010.08.0043
  • Articles

▼Agomelatine for major depressive episodes

  • Relevant BNF section: BNF 4.3.4

Abstract

▼Agomelatine (Valdoxan - Servier) is an antidepressant licensed for treating patients with major depressive episodes. The drug company's website for agomelatine states that the drug acts simultaneously as a melatonin receptor agonist and a serotonin receptor antagonist and claims that it is a “major therapeutic advance in management of depression through the restoration of circadian rhythms”.1 Here we consider whether agomelatine offers significant advantage for patients with major depressive episodes.

Footnotes